Feb 01, 2019 8:00am EST OPKO Health Receives FDA Approval for the Point-of-Care Sangia PSA Test with the Claros® 1 Analyzer
Jan 31, 2019 9:15pm EST OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator
Jan 07, 2019 6:00am EST OPKO Health Appoints Jon R. Cohen, M.D. Executive Chairman of BioReference Laboratories
Dec 27, 2018 4:34pm EST OPKO Health and OPKO's CEO and Chairman, Dr. Phillip Frost, Announce Proposed Resolution of SEC Action
Nov 08, 2018 12:30pm EST BioReference Laboratories Named as Preferred Laboratory with Horizon Healthcare Services
Nov 08, 2018 9:12am EST OPKO Health to Announce Third Quarter 2018 Financial Results on November 9, 2018